Health Archive » May, 2008

Health - May, 2008

172 articles

• Merck, Fosamax Plaintiffs Clash Over Discovery
• Court Rules Appeal Of Arriva Bankruptcy Plan Moot
• WellPoint Hit With ERISA Suit Over March Stock Drop
• Judge Nixes RICO Class Action Against Blue Cross
• Oxford Gene Sues BioArray Over BeadChip Patent
• FDA Wants To Reclassify Digital Mammograms
• California Senate Mulls Sick Leave Bill
• Wyeth Sues Sandoz Over Contraceptive Patent
• Ex-Hospital CEO Charged With Dodging $64M Order
• Vioxx Deal Holds Up Even After Appeals Wins: Experts
• Draft Guidance On Certification Creates Ambiguity
• First DataBank Pays Over $1M To Settle AWP Case
• Judge Rules Stanford's HIV Test Patents Obvious
• Two Courts Overturn Vioxx Rulings Against Merck
• FDA Warns Steris Over Sterilization Device
• Court Certifies Classes in Monsanto Pension Plan Suit
• Connecticut Says McKesson Inflated Drug Prices
• FDA Seeks To Amend Drugs' Pregnancy Labeling
• Diversion Of Ambulance Can Violate EMTALA
• Drugmakers File 2nd Suit To Thwart Generic Xyzal
• DLA Piper's Schulman Joins Pfizer As GC
• FDA Seeks Recall Of 'Illegal' ED Drug
• Medtronic Wins $250M From Boston Scientific
• Wyeth Makes Its Case For Preemption To High Court
• Australian Court Upholds Pfizer's Lipitor Patent
• AstraZeneca Sues Barr Over Crohn's Disease Drug
• Two More From Perkins Coie Join King & Spalding
• Vote Looms Over Right To Sell Prescription Info
• Germany Fines Bayer $16M On Price-Fixing Charges
• Ex-Connetics VP Settles Insider Trading Charges
• Express Scripts Settles Drug-Switch Case For $9.5M
• OIG's Changes Improve Self-Disclosure Protocol
• 3rd Circuit Rejects Isolagen Appeal As Premature
• Abbott, Roche Settle Glucose Test Patent Dispute
• Plaintiffs Win Partial Victory In E-Ferol Class Action
• MedImmune, Genentech Strike Deal In Synagis Case
• FDA, Medicare Launch Drug Safety Initiative
• Medtronic's Impact On Medical Device Manufacturers
• GE Sues To Invalidate SonoSite Ultrasound Patent
• Consulting Firm Exits Medical Monitoring Suit
• Judge Keeps Failure-To-Warn Claim In Baxter Suit
• Pfizer Using Quigley Co. To Dodge Claims: Insurer
• Baxter Sues Talecris Over Blood Test Patents
• 9th Circuit Scraps Antitrust Suit Against Providence
• Icahn Forces Biogen's Hand In Document Spat
• Wilson Sonsini Adds Mylan's Ex-Chief Legal Officer
• Medtronic Shells Out $75M In Qui Tam Deal
• Zyprexa 3rd-Party Payers' Class Bid Draws Flak
• Report Links Chantix To Seizures, Heart Trouble
• Aredia MDL Parties Select First 10 Cases For Trial
• Fosamax Plaintiffs Try To Force Merck's Hand
• Merck Wins U.K. Appeal For Propecia Patent
• Brand-Name, Generics Deals Stifle Competition: FTC
• Bausch & Lomb Looks Askance At Patent Stay Ruling
• Lawmakers Ask Drug Companies To Improve Ads
• Fresenius Must Hand Over Epogen Docs: 8th Circuit
• 9th Circuit Rejects NLRB's Ruling On Button Ban
• Mirapex Plaintiffs Add Punitive Damages To Claim
• Merck Settles With States Over Vioxx Marketing
• Wyeth Calls For End To Discovery In Prempro MDL
• Wyeth, Nycomed Take Aim At Sandoz Over Protonix
• Hospitals Have Mandamus Relief: Texas High Court
• Judge Nixes Abbott's Patent Defense In Norvir Case
• McKesson Plotted To Fix Drug Prices, City Claims
• Pfizer Still Safe From Quigley Suit, Judge Rules
• 5th Circ. Upholds Ruling Against Texas Doctors Group
• Judge Finalizes $2.25M Cardia Settlement
• 'No Reliance' Defense Defeats Class Certification
• Judge Blasts Parties For Delay In Guidant MDL
• Companies Fined For Water Contamination In Arizona
• FDA Stresses Dangers Of Transplant Drugs
• Mix-Up Leads To Acne Medication Recall
• Appeals Court Denies Full Pay For Emergency Services
• Leiner Can Offer Stalking Horse Breakup Fee: Judge
• Order May Clarify Southern Calif. Patent Local Rules
• FDA Shuts Down Unlicensed Cough Medicine Co.
• Biovail To Pay $24.6M Over Cardizem Marketing
• Nutraceutical Stock Promoter To Pay Over $2M
• 9th Circ. Grants L.A. Biomed New Graft Patent Trial
• Court Won't Enjoin Nova In Glucose Meter Fight
• Salix Sues Novel Labs Over Bowel Cleanser Patent
• Judge Tosses Nearly All Of J&J's Red Cross Claims
• McKesson Ruling Still Poses Challenges For IP Lawyers
• FDA's Exclusivity Forfeiture Saga Continues
• Judge Tinkers With Stent Claim Order Again
• EU Steps Up Antitrust Probe Of Drug Market
• Bayer Pulls Remaining Trasylol From U.S. Market
• FDA Puts Immucor On Notice For Safety Violations
• Peer Review Protections After Amendment 7
• Appeals Court Overturns $7.75M Vioxx Ruling
• Fen-Phen Lawyers' Fraud Trial Gets Under Way
• Federal Circuit Affirms Aventis' Inequitable Conduct
• Kids' Respiratory Problems Surge After Katrina: CDC
• FTC Furthers Probe Into Mylan's Keppra Settlement
• U.S. Gives Opinion On Qui Tam Pfizer Suit
• Atrium Withdraws Some Catheters For Heparin Fears
• Fed. Circ. Revives Stryker-Acumed Nail Patent Case
• Labeling Changes And FDA's Oversight Of Drug Safety
• Court Lets Bone-Cleaning Firm Add Patent To Suit
• Zimmer Fights Class Action Following Kickback Probe
• Fed. Circ. Upholds Diazyme Win On Assays Patents
• Medical Dye Makers Face Another Liability Suit
• Suit Claims CareCore Strangled Competition
• Supreme Court Declines To Hear Apotex Appeal
• Leiner Settles DOJ Probe Into Drug Plant Violations
• E-Prescribing's Dirty Little Secret
• Zyprexa Lawyers Renew Quest For Additional Fees
• Justice Recusals Allow Apartheid Claims To Continue
• StemCells Fires Back At Neuralstem Over New Patent
• Invitrogen Strikes Deal For Stem Cell Patents
• SEC Accuses Doctors Of Insider Trading
• 5 Years On, Trademark Fraud Ruling Still Resonates
• Glycoproducts Infringed Mannatech Patent: Jury
• Litigators Urge Clarity Over Punitive Damage Rules
• Policy Proxy Bids Waste Company Time: Experts
• Bausch & Lomb Told To Turn Over Disputed Docs
• Barr Eyes Mid-2008 Launch For Generic Yasmin
• FTC Tries To Stop Virginia Hospital Deal
• Pain Pumps: The Next Medical Device Litigation Wave?
• Canadian Court Nixes J&J Suit V. Boston Scientific
• Schering-Plough Sued Over Coppertone Trade Dress
• Federal Circuit Weighs Limits On Business Methods
• Lawmakers Grill Pharma Execs Over Drug Ads
• Ephedra MDL Nears End With Score Of Dismissals
• Lawmakers Fight FDA's Anti-Estriol Stance
• Medtronic Yanks Heparin-Coated Cardiac Devices
• Judge Certifies Wellbutrin Antitrust Class Action
• Lilly Fails To Halt Maine Zyprexa Wrongful-Death Suit
• The FTC's Ongoing Opposition To Reverse Payments
• EC To Simplify Medical Device Legislation
• Judge Trashes Requests For Extra Attorneys' Fees
• 6th Circ. Tosses Antitrust Suit Against PPO
• Teva Sues To Invalidate Nexium Patents
• Bladder Drugs May Hasten Decline Of Aged: Study
• Prescription Drug Preemption Awaits Resolution
• Federal Circuit Won't Rehear Celebrex Patent Dispute
• Co-Counsel Joins Outcry Over Fees In Guidant MDL
• FDA Panel Rejects New Uses For Cancer Drug
• AGs Examining J&J Nominal Pricing Deals
• ImClone Cries Fraud Over Erbitux Deal
• Alphatec To Pay $11M In Spinal Screw Patent Deal
• Schneider & Wallace Calls Guidant Fees Unfair
• Another Symbicort Patent Revoked In EU
• WIPO Clears Boston Scientific Of Infringement
• Neuralstem Seeks To Restart Stayed Patent Suit
• PSN Porcelain Veneer Patent Noninfringed: Fed Circ.
• Ocean Tomo Offers New Site For Patent Transactions
• A Big Leap For E-Pedigree Standards, Technologies
• Procter & Gamble Targets J&J's Tooth Whitener
• Big Pharma To Defend Ad Practices At House Hearing
• McKesson Ponies Up $13M To Settle Drug Claims
• New Study Ties Biofilms To Jaw Deterioration
• Jones Day Health Group Co-Chair Lured To Skadden
• FDA Warns Stryker Again Over Quality Control
• Pharmacists' Right To Refuse Plan B Upheld
• FDA Takes It On The Chin In Endotec Ruling
• Pfizer Settling Celebrex, Bextra Claims: Report
• Antitrust Lyme Disease Probe Sparks Debate
• Invitrogen Scientist Settles Insider Trading Case
• Wider Fentora Use Could Encourage Abuse: FDA
• Sanofi-Aventis Sues Over Eloxatin Ingredient
• Judge Denies Delaying Trial For Fen-Phen Lawyers
• 3 Things Could Make Or Break An ANDA
• FDA Scolds Merck About Conditions At Pa. Plant
• Dietary Products Tainted With Chromium: FDA
• The Best And Worst Patents For Generics To Fight
• Zyprexa Securities Suit Dismissed As Time-Barred
• Genetic Bias Bill Passes House With Ease
• Health Insurers Accused Of Reimbursement Fraud
• Sepracor, Breath Settle Xopenex Patent Fight
• In Cephalon Case, FTC Hopes For High Court Ruling
• Judges' Top Four Pet Peeves In Patent Litigation